LC
AVDL

Lindbrook Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Lindbrook Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.15K Buy
274
+58
+27% +$486 ﹤0.01% 2265
2024
Q4 		$2.27K Buy
216
+118
+120% +$1.43K ﹤0.01% 2274
2024
Q3 		$1.28K Hold
98
– – ﹤0.01% 2452
2024
Q2 		$1.38K Hold
98
– – ﹤0.01% 2439
2024
Q1 		$1.66K Hold
98
– – ﹤0.01% 2306
2023
Q4 		$1.38K Hold
98
– – ﹤0.01% 2387
2023
Q3 		$1.01K Hold
98
– – ﹤0.01% 2358
2023
Q2 		$1.61K Sell
98
-2,000
-95% -$26K ﹤0.01% 2232
2023
Q1 		$19.2K Buy
2,098
+200
+11% +$1.64K ﹤0.01% 1096
2022
Q4 		$13.6K Sell
1,898
-188
-9% -$1.32K ﹤0.01% 1278
2022
Q3 		$10K Buy
2,086
+286
+16% +$1.57K ﹤0.01% 1309
2022
Q2 		$4K Buy
+1,800
New +$7.39K ﹤0.01% 1612

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lindbrook Capital's AVDL Position: Q1 2025 in Review

Lindbrook Capital increased its Avadel Pharmaceuticals (AVDL) stake by 27% in Q1 2025, buying an estimated $486 and bringing the position to 274 shares worth $2.15K. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Lindbrook Capital first reported a position in AVDL in Q2 2022 and has held it in 12 quarters since. The position peaked at $19.2K in Q1 2023. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Lindbrook Capital held 274 shares of Avadel Pharmaceuticals worth $2.15K as of Q1 2025.
  • Lindbrook Capital bought 58 Avadel Pharmaceuticals shares in Q1 2025, an estimated $486.
  • Avadel Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2265 holding.
  • Lindbrook Capital first reported a position in Avadel Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
  • Lindbrook Capital's Avadel Pharmaceuticals position peaked at $19.2K in Q1 2023.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.